Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
04 August, 2015 03:08 IST
Protonix settlement a blow to Sun Pharma's near-term acquisition plans
Source: IRIS | 13 Jun, 2013, 10.27AM
Comments  |  Post Comment

Sun Pharmaceutical Industries said Wednesday the company settled litigation pending in the United States District Court, District of New Jersey (Court) regarding Sun Pharma (Q,N,C,F)* subsidiary's generic pantoprazole. Sun Pharma will pay USD 550 million to Pfizer Inc and Atlanta Pharma AG as a part of this settlement. It will continue to sell its generic pantoprazole in the U.S.

In 2005, Wyeth and Altana had filed a patent infringement suit against Sun after it filed its ANDA for Pantoprazole. Sun launched its generic Pantoprazole in the US on Jan. 30, 2008 at risk. In April 2010, a jury had determined that Altana's patent was valid. Wyeth had sought USD 960 million for the so called infringement. The Protonix patent had expired in January 2011. On Jun. 3, 2013, the court began a jury trial to assess the amount of past damages that Sun Pharma owed for infringing Altana's now expired patent. The settlement has effectively neutralised the ongoing litigation. Sun has already provided for USD 107 million in Q2FY13.

Commenting on the development, ICICIdirect said, ''As the settlement amount is unprecedented, the stock is likely to witness knee-jerk reaction in the near term. However, the event was not entirely unexpected. Sun will have to shell out Rs 30 billion out of its cash pile of Rs 54 billion as on Mar. 31, 2013, thus effectively putting its immediate acquisition plans in jeopardy. We have cut our FY14E and FY15E EPS estimates by Rs 27 and Rs 5, respectively, owing to a dent in other income (treasury income). Our revised target price now stands at Rs  976 i.e. 23x FY15E (revised) EPS of Rs 42.4. We maintain Hold. Any swift correction can be used as an opportunity to re-enter the stock as all other strongholds remain intact.''

It has maintained 'Hold' on Sun Pharmaceuticals with target price of Rs 976 as against current market price (CMP) of Rs 981 in its report.

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Hero Motocorp quarterly earnings climb 33.33% - 03-Aug-2015 19:56
Emkay Global retains 'Accumulate' on Ashoka Buildcon - 03-Aug-2015 19:02
Kalindee Rail Nirman (Engineers) loss widens in Apr-Jun quarter - 03-Aug-2015 18:03
P N B Gilts swings to loss in Apr-Jun quarter - 03-Aug-2015 17:58
3M India quarterly net surges 55.23% - 03-Aug-2015 17:50
Shriram Transport arm launches new Automall facility in Patancheru - 03-Aug-2015 17:31
Bharti Airtel names Manish Khera as CEO - 03-Aug-2015 17:27
Indiabulls Real Estate quarterly profit soars 2.33 times - 03-Aug-2015 17:18
Confident of beating industry growth rate: Sunil Bhatia, Blue Star Infotech - 03-Aug-2015 16:57
ICICIdirect recommends 'Hold' on Syndicate Bank; cuts target to Rs 100 - 03-Aug-2015 16:35
BGR Energy Systems quarterly profit up 24.48% - 03-Aug-2015 16:23
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer